Literature DB >> 34450120

A Randomized Controlled Trial of Precision Vestibular Rehabilitation in Adolescents following Concussion: Preliminary Findings.

Anthony P Kontos1, Shawn R Eagle2, Anne Mucha3, Victoria Kochick3, Jessica Reichard4, Claire Moldolvan4, Cyndi L Holland2, Nicholas A Blaney2, Michael W Collins3.   

Abstract

OBJECTIVE: To compare the effectiveness of a 4-week precision vestibular rehabilitation intervention compared with a behavioral management control intervention for adolescents with vestibular symptoms/impairment within 21 days of a concussion. STUDY
DESIGN: This study used double-blind, randomized controlled trial design involving adolescent (12-18 years) patients with a diagnosed sport/recreation-related concussion with vestibular symptoms/impairment from a concussion-specialty clinic between October 2018 and February 2020. Eligible participants were randomized in a 1:1 to either a 4-week vestibular intervention group (VESTIB) or a behavioral management control group (CONTROL). CONTROLS (n = 25) were prescribed behavioral management strategies (eg, physical activity, sleep, hydration, nutrition, stress management) and instructed to perform stretching/physical activity (eg, walking, stationary cycle) 30 minutes/day. VESTIB (n = 25) were prescribed precision vestibular rehabilitation exercises and instructed to perform at-home exercises for 30 minutes/day. Primary outcomes were improvement in Vestibular/Ocular Motor Screening vestibular items (ie, horizontal/vertical vestibular-ocular reflex, visual motion sensitivity) at 4 weeks postenrollment.
RESULTS: We screened 310 and enrolled a total of 55 (18%) adolescent patients who were randomized to one of the interventions. Fifty of fifty-five (91%) participants completed all aspects of the study protocol. Participants in VESTIB improved significantly across the intervention period in horizontal (mean difference-1.628; 95% CI [-3.20, -0.06]; P = .04) and vertical (mean difference-2.24; 95% CI [-4.01, -0.48]; P = .01) vestibular-ocular reflex, but not visual motion sensitivity (mean difference-2.03; 95% CI [-4.26, 0.19]) of the Vestibular/Ocular Motor Screening score compared with CONTROLS.
CONCLUSIONS: Overall, the vestibular intervention group experienced greater clinical improvements in vestibular symptoms/impairment than controls across the 4-week intervention. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03555370.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34450120     DOI: 10.1016/j.jpeds.2021.08.032

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Trajectories of Visual and Vestibular Markers of Youth Concussion.

Authors:  Kristy B Arbogast; Riddhi P Ghosh; Daniel J Corwin; Catherine C McDonald; Fairuz N Mohammed; Susan S Margulies; Ian Barnett; Christina L Master
Journal:  J Neurotrauma       Date:  2022-10       Impact factor: 4.869

2.  Concussion and Sport: Progress is Evident.

Authors:  Philip J O'Halloran; Anthony P Kontos; Michael W Collins
Journal:  Sports Med       Date:  2022-06-20       Impact factor: 11.928

3.  Free-living gait does not differentiate chronic mTBI patients compared to healthy controls.

Authors:  Dylan Powell; Alan Godfrey; Lucy Parrington; Kody R Campbell; Laurie A King; Sam Stuart
Journal:  J Neuroeng Rehabil       Date:  2022-05-26       Impact factor: 5.208

4.  Characterizing the evolution of oculomotor and vestibulo-ocular function over time in children and adolescents after a mild traumatic brain injury.

Authors:  Adrienne Crampton; Kathryn J Schneider; Lisa Grilli; Mathilde Chevignard; Michal Katz-Leurer; Miriam H Beauchamp; Chantel Debert; Isabelle J Gagnon
Journal:  Front Neurol       Date:  2022-07-19       Impact factor: 4.086

5.  The effects of augmenting traditional rehabilitation with audio biofeedback in people with persistent imbalance following mild traumatic brain injury.

Authors:  Kody R Campbell; Robert J Peterka; Peter C Fino; Lucy Parrington; Jennifer L Wilhelm; Natalie C Pettigrew; Laurie A King
Journal:  Front Neurol       Date:  2022-10-04       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.